ArticleJournal of translational medicine2025
Serum vesicle biomarkers reflect the disease activity of idiopathic pulmonary fibrosis.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- How extracellular vesicles contribute to pulmonary fibrosis: miRNA-mediated mechanisms, diagnostic potential, and emerging therapeutic strategies.Molecular biology reports · 2026Review
- RNA Modifications as Molecular Regulators of Alveolar Epithelial Injury and Aberrant Repair in Pulmonary Fibrosis.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
43 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdiopathic pulmonary fibrosis (IPF) is a heterogeneous disease caused by an interplay of genetic and environmental factors. Biomarkers that reflect the progression of fibrosis are required for the management of IPF.
methodsWe extracted serum extracellular vesicles from a discovery cohort (127 IPF patients and 34 controls) and a validation cohort (20 IPF patients and 22 controls). Non-targeted proteomic analysis was performed by a data-independent acquisition method. We investigated the proteomic profiles in relation to multiple clinical parameters associated with IPF. To further evaluate the biological relevance of the identified biomarkers, we analyzed publicly available single-cell RNA sequencing datasets of lung tissue and conducted immunochemical validation using our collected lung samples.
resultsWe obtained 2420 protein profiles in serum extracellular vesicles and identified 19 IPF-associated proteins; their expressions were significantly lung-specific. Protein module analyses revealed that the upstream components of the complement system were increased in IPF. These IPF-associated proteins were involved in various IPF-associated genes and heterogeneously increased in IPF patients. Notably, surfactant protein B (SFTPB) not only showed superior diagnostic performance over the existing marker but was also significantly associated with progressive disease activity, such as the extent of fibrosis and decline in lung function. Furthermore, single-cell RNA-sequencing analysis revealed that SFTPB was associated with the TGF-β/SMAD pathway in SCGB3A2 + cells in IPF lungs. SFTPB expression in SCGB3A2 + cells was confirmed by immunostaining.
conclusionsSerum extracellular vesicles could capture heterogenetic fibrotic profiles in IPF, and SFTPB can be a promising biomarker reflecting the disease activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.